Brief: Cross Country Healthcare Q2 Adjusted EPS USD -0.01 Vs. IBES Estimate USD 0.05

Cross Country Healthcare

06/08/2025 21:15

Overview

Cross Country Q2 revenue falls 19% yr/yr, missing analyst expectations

Adjusted EPS for Q2 was a loss of $0.01, missing estimates

Strong Homecare Staffing performance with revenue up over 30% yr/yr

Outlook

Company will not provide forward-looking guidance due to pending Aya merger

Cross Country expects Aya merger to close in Q4 2025

Result Drivers

HOMECARE STAFFING - Revenue grew more than 30% yr/yr, driven by strong performance

PHYSICIAN STAFFING - Experienced 3% yr/yr revenue growth due to favorable mix and price

COST CONTROL - 5% sequential decline in SG&A expenses attributed to leverage of low-cost center in India

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$274.07 mln
$290.40 mln (6 Analysts)
Q2 Adjusted EPS
Miss
-$0.01
$0.05 (6 Analysts)
Q2 EPS
-$0.2
Q2 Net Income
-$6.66 mln
Q2 Adjusted EBITDA
Miss
$7.59 mln
$8.81 mln (6 Analysts)
Q2 Gross Margin
20.4%
Q2 Adjusted EBITDA Margin
2.8%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the employment services peer group is "buy."

Wall Street's median 12-month price target for Cross Country Healthcare Inc is $18.61, about 31% above its August 5 closing price of $12.84

The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 31 three months ago

Press Release: ID:nBw5jmX1ra

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)